source
- AbbVie receives FDA approval for ultra-rare blood cancer ADC acquired from ImmunoGenAbbVie announced that the U.S. Food and Drug Administration has granted approval for an antibody-drug conjugate targeting an ultra-rare, aggressive form of blood cancer. The therapy was obtained t…
- Signos secures $20 million to advance GLP-1-focused wearable platform amid broader wearables interestThe article notes that two wearable‑related developments are being discussed, and both involve GLP‑1 therapies. Signos announced it has raised $20 million to fund its approach that combines wearab…